



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/801,379	03/15/2004	Iddys D. Figueroa	200401492-1	3171
<div>7590 12/19/2006 HEWLETT-PACKARD COMPANY Intellectual Property Administration P.O. Box 272400 Fort Collins, CO 80527-2400</div>			<div>EXAMINER CAMERON, ERMA C</div> <div>ART UNIT 1762 PAPER NUMBER</div>	
SHORTENED STATUTORY PERIOD OF RESPONSE		MAIL DATE	DELIVERY MODE	
3 MONTHS		12/19/2006	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

Office Action Summary

Application No.

10/801,379

Applicant(s)

FIGUEROA ET AL.

Examiner

Erma Cameron

Art Unit

1762

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 05 October 2006.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-7 and 25-29 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-7 and 25-29 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
 - ☐ Certified copies of the priority documents have been received in Application No. _____.
 - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Response to Amendment

Double Patenting

1. The terminal disclaimers to 10/801380 and 10/801381 have been received and approved.

Claim Rejections - 35 USC § 112

2. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
3. The rejection of Claim 25 under 35 U.S.C. 112, second paragraph, is withdrawn because of the amendment filed 10/5/2006.

Claim Rejections - 35 USC § 102/103

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

4. Claims 1-2, 4-7 and 25-29 are rejected under 35 U.S.C. 102(b) as anticipated by or, in the alternative, under 35 U.S.C. 103(a) as obvious over Voss et al. (4,322,449).

Voss teaches a method of applying a bioactive agent to a delivery substrate in the form of dots forming a desired geometrical pattern (abstract; throughout; col. 5, lines 35-37). Voss teaches the control of various parameters, such as dots/second, volume/drop, number of ejection strokes, etc. As is known in the art and as taught in the specification, controlling the dot pattern, the size or shape of the dot, or the consistency of the size of the dots will inherently provide control over the dissolution rate. The precise nature of Voss' printing technique yields such control.

As for the limitation of first "identifying a target dissolution rate", Examiner notes that safe and effective administration of drug (bioactive agent) to a patient requires a precise dose at an acceptable "target" dissolution rate. Medical professionals, such as doctors, pharmacists, and pharmaceutical company scientists, are of ordinary skill in this art. Medical personnel would have been aware that a too-rapid dissolution rate could lead to an over-dose, whereas a too-slow dissolution rate could lead to ineffective treatment levels. Neither of these risks is acceptable. Also, many medications are provided in a controlled release (CR) form to provide the correct dose over a period of time, inherently requiring the use of a target dissolution rate. Therefore, when creating a drug delivery substrate, it is Examiner's position that it would have been inherent for one of ordinary skill in the art to identify, in addition to a desired target dose, a target dissolution rate. The patterns of dots placed down on the delivery substrate of Voss would have been inherently placed to achieve said target dissolution rate for the safety and health of patients.

In the alternative, for all the reasons stated above, it is Examiner's position that it would have been obvious to one of ordinary skill in the art to select a target dissolution rate to be

Art Unit: 1762

achieved by the patterns of Voss to ensure the safe and effective administration of drugs to patients.

One of ordinary skill in the art would have been well aware of the effects of surface area on dissolution rate, for example, that a plurality of small, thin dots would dissolve faster than a thick, large dot of the same total volume. As evidence of this awareness, as outlined above, Voss teaches control of the parameters that would have been known by ordinary artisans in the medical coating art at the time the invention was filed to impact dissolution rate.

Voss' method produces less than 1% deviation from average (Ex. 3)

Voss teaches the use of a piezoelectric ejection element (abstract).

Voss provides the bioactive agent in a solvent (col. 5, lines 52-62), that inherently dries by evaporation, with precisely controlled concentration and drop volume (col. 6, line 5).

Regarding claim 25, a pattern will inherently impact the dissolution rate speed.

The active substance may be ground and suspended (5:50-55), thus controlling crystal morphology.

Claim Rejections - 35 USC § 103

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

Art Unit: 1762

5. Claim 3 is rejected under 35 U.S.C. 103(a) as being unpatentable over Voss, as applied above, in view of Voges (5,894,841).

Examiner maintains the rejection of the previous office action, which is re-stated herein: Voss teaches that which is disclosed above, namely forming droplets of bioactive agent using piezoelectric ejection elements. What Voss does not teach is the use of thermal ejection elements.

It is Examiner's position that these two species of inkjet printing are obvious variants that would have been known to an ordinary artisan and cites Voges for teaching the same. Voges teaches a method of forming droplets of bioactive agent by using one of the two forms of inkjet printing, namely either a piezoelectric ejection device or a thermal ejection device. Since Voss teaches printing precise drops of bioactive agent using a piezoelectric element, such as is used in inkjet printing, and Voges teaches that either the piezoelectric or thermal types of inkjet printing are suitable for forming precise droplets of bioactive agent, Voges would have reasonably suggested the use of a thermal element in the method of Voss. It would have been obvious to one of ordinary skill in the art to use the interchangeability teachings of Voges in the method of Voss to provide Voss with a suitable, successful alternative element for dosing dots in a precise manner.

Response to Arguments

6. The applicant has argued that Voss does not identify a target dissolution rate. The examiner disagrees in that the precise dosing of the active substance, with precise control over

Art Unit: 1762

volume, spacing and concentration will have the effect of controlling the dissolution rate of the active substance, and these parameters are therefore selected with this control in mind. The applicant has also argued that Voss does not select a desired dot topography. The examiner would point to Voss's printing of dots in the form of letters (see Example 2) as one example of controlling dot topography.

Conclusion

7. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire **THREE MONTHS** from the mailing date of this action. In the event a first reply is filed within **TWO MONTHS** of the mailing date of this final action and the advisory action is not mailed until after the end of the **THREE-MONTH** shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than **SIX MONTHS** from the mailing date of this final action.

Art Unit: 1762

8. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Erma Cameron whose telephone number is 571-272-1416. The examiner can normally be reached on 8:30-6:00, alternate Fridays off.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Timothy Meeks can be reached on 571-272-1423. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Erma Cameron
ERMA CAMERON
PRIMARY EXAMINER

Erma Cameron
Primary Examiner
Art Unit 1762

December 18, 2006